FG Onco Tamoxifen

Pharmacogenetics of tamoxifen treatment

SYNLAB
SOLUTIONS IN DIAGNOSTICS

www.synlanb-sd.com

Why undergoing this examination?

Tamoxifen is the most commonly used selective modulator in breast cancer treatment. One of the main causes of interindividual response differences to tamoxifen is the presence of alleles in the CYP2D6 gene associated with null, decreased, or increased enzymatic activity compared to normal. The CYP2D6 gene encodes the CYP2D6 enzyme, which converts tamoxifen into endoxifen, its active metabolite and the primary contributor to its anti-neoplastic activity. Consequently, a decrease in CYP2D6 enzyme activity results in reduced efficacy of tamoxifen treatment.

What is the exam?

The **FG Onco Tamoxifen** genetic profile studies the 11 main allelic variants of the ***CYP2D6*** gene with known clinical relevance. These 11 allelic variants cover over 97% of all alleles described in this gene. The goal of the analysis is to identify patients with an increased likelihood of reduced tamoxifen treatment efficacy and the development of serious side effects.

For whom is it indicated?

- Patients undergoing pharmacological treatment that does not yield expected results;
- Patients experiencing drug-related side effects.

Technology

Next-generation sequencing (NGS)

Advantages

SYNLAB GROUP

Guaranteed by the experience of the absolute European leader in laboratory diagnostics.

COMPLETE

Detailed report, where the results will suggest individualized courses of action, aiding in prognosis for greater treatment efficacy and a significant reduction in adverse reactions.

Extra Information

DOCUMENTATION - Available on the SYNLAB Direct for clients

- Informed Consent;
- Clinical Questionnaire;
- Medical prescription.

PREPARATION

- Fasting is not necessary for the exam.

Delivery Time
12 business days

Sample Type
5 mL of whole blood in EDTA